Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Evaluation of EuroFlow minimal residual disease measurement and donor chimerism monitoring following tandem auto-allogeneic transplantation for multiple myeloma

Bone Marrow Transplantation volume 56, pages 1116–1125 (2021)Cite this article

Subjects

Abstract

Prognostic factors for multiple myeloma (MM) after allogeneic haemopoietic stem cell transplantation (alloHSCT) are poorly characterised. Two potential factors include minimal residual disease (MRD) and CD3+ donor-specific chimerism. We retrospectively examined 93 consecutive patients who received upfront or deferred tandem auto-alloHSCT. Bone marrow (Euroflow) MRD was assessed pre-alloHSCT and 3-monthly post-alloHSCT. CD3+ donor chimerism was assessed at D30, D60, D90, 6 m and 12 m post-alloHSCT. There was no statistical difference between upfront and deferred transplants in progression free survival (PFS) (34 m vs. 15 m respectively, p = 0.20) and overall survival (OS) (75.5 m vs. 62.7 m respectively, p = 0.56). Patients who were MRD-positive post-alloHSCT had inferior PFS to MRD-negative patients from 6 m (6 m HR 3.32, p = 0.02; 9 m HR 4.08, p = 0.003; 12 m HR 4.47, p = 0.008). Attainment or maintenance of MRD-negativity predicted reduced relapse risk (23.5% vs. 62.5%, p = 0.04). However, there was no significant difference in OS between the MRD-negative and positive groups. Full CD3+ donor chimerism at early time points (D30 and D90) was associated with increased risk of acute GVHD (D30 p < 0.001, D90 p = 0.006) and extensive chronic GVHD (D90 p = 0.04), but not PFS or OS. These data support the use of sequential MRD evaluation post-alloHSCT to inform intervention to eradicate persistent or emergent MRD-positive disease.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Major outcomes by transplant indication.
Fig. 2: Comparison of outcomes according to pre-alloHSCT MRD status.
Fig. 3: Comparison of PFS according to post-alloHSCT MRD status.
Fig. 4: Flow chart demonstrating the MRD trends of patients in the first 12 months of alloHSCT.
Fig. 5: Comparison of OS according to post-alloHSCT MRD status.
Fig. 6: Cumulative incidence of aGVHD and extensive cGVHD according to CD3+ donor chimerism.

Similar content being viewed by others

References

  1. Fonseca R, Abouzaid S, Bonafede M, Cai Q, Parikh K, Cosler L, et al. Trends in overall survival and costs of multiple myeloma, 2000–2014. Leukemia. 2017;31:1915–21.

    Article  CAS  Google Scholar 

  2. Turesson I, Bjorkholm M, Blimark CH, Kristinsson S, Velez R, Landgren O. Rapidly changing myeloma epidemiology in the general population: increased incidence, older patients, and longer survival. Eur J Haematol. 2018;101:237–44.

    Article  Google Scholar 

  3. Aggarwal M, Agrawal N, Yadav N, Verma P, Ahmed R, Mehta P, et al. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma. Ann Hematol. 2018;97:1869–77.

    Article  CAS  Google Scholar 

  4. Schönland SO, Iacobelli S, Koster L, Blaise D, Potter M, Cornelissen J, et al. Comparison of different upfront transplant strategies in multiple myeloma - a large registry study from chronic malignancies working party of EBMT. Blood 2019;134(Supplement_1):324. https://doi.org/10.1182/blood-2019-128795.

  5. annual data summary «ABMTRR. http://www.abmtrr.org/index.php/annual-data-summary/. Accessed 28 Mar 2020.

  6. Greipp PR, Miguel JS, Dune BGM, Crowley JJ, Barlogie B, Bladé J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412–20.

    Article  Google Scholar 

  7. Moreau P, Cavo M, Sonneveld P, Rosinol L, Attal M, Pezzi A, et al. Combination of International Scoring System 3, highlactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death. J Clin Oncol. 2014;32:2173–80.

    Article  CAS  Google Scholar 

  8. Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014;28:269–77.

    Article  CAS  Google Scholar 

  9. Jimenez-Zepeda VH, Mikhael J, Winter A, Franke N, Masih-Khan E, Trudel S, et al. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival. Biol Blood Marrow Transpl. 2012;18:773–9.

    Article  Google Scholar 

  10. Lemieux E, Hulin C, Caillot D, Tardy S, Dorvaux V, Michel J, et al. Autologous stem cell transplantation: an effective salvage therapy in multiple myeloma. Biol Blood Marrow Transpl. 2013;19:445–9.

    Article  CAS  Google Scholar 

  11. Munshi NC, Avet-Loiseau H, Rawstron AC, Owen RG, Child JA, Thakurta A, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol. 2017;3:28–35.

    Article  Google Scholar 

  12. Rawstron AC, Gregory WM, De Tute RM, Davies FE, Bell SE, Drayson MT, et al. Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction. Blood 2015;125:1932–5.

    Article  CAS  Google Scholar 

  13. Maffini E, Storer BE, Sandmaier BM, Bruno B, Sahebi F, Shizuru JA, et al. Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma. Haematologica 2019;104:380–91.

    Article  CAS  Google Scholar 

  14. Dhakal B, D’Souza A, Martens M, Kapke J, Harrington AM, Pasquini M, et al. Allogeneic hematopoietic cell transplantation in multiple myeloma: impact of disease risk and post allograft minimal residual disease on survival. Clin Lymphoma Myeloma Leuk. 2016;16:379–86.

    Article  Google Scholar 

  15. Lee HC, Saliba RM, Rondon G, Chen J, Charafeddine Y, Medeiros LJ, et al. Mixed T lymphocyte chimerism after allogeneic hematopoietic transplantation is predictive for relapse of acute myeloid leukemia and myelodysplastic syndromes. Biol Blood Marrow Transpl. 2015;21:1948–54.

    Article  Google Scholar 

  16. Huisman C, de Weger RA, de Vries L, Tilanus MGJ, Verdonck LF. Chimerism analysis within 6 months of allogeneic stem cell transplantation predicts relapse in acute myeloid leukemia. Bone Marrow Transpl. 2007;39:285–91.

    Article  CAS  Google Scholar 

  17. Mackinnon S, Barnett L, Heller G, O’reilly RJ. Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukemia. Blood. 1994;83:3409–16.

  18. Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, García-Sánchez O, Böttcher S, et al. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31:2094–103.

    Article  CAS  Google Scholar 

  19. Thiede C, Florek M, Bornhäuser M, Ritter M, Mohr B, Brendel C, et al. Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection. Bone Marrow Transpl. 1999;23:1055–60.

    Article  CAS  Google Scholar 

  20. Dhakal B, Vesole DH, Hari PN. Allogeneic stem cell transplantation for multiple myeloma: Is there a future? Bone Marrow Transpl. 2016;51:492–500.

    Article  CAS  Google Scholar 

  21. Costa LJ, Iacobelli S, Pasquini MC, Modi R, Giaccone L, Blade J, et al. Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation. Bone Marrow Transplant. 2020;55:1–7.

  22. Kuiper R, Van Duin M, Van Vliet MH, Broijl A, Van Der Holt B, Jarari L El, et al. Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System. Blood. 2015;126:1996–2004.

  23. Bygrave CA, Pawlyn C, Davies FE, Cairns D, Striha A, Hockaday A, et al. Progression free survival below 12 months following stem cell transplant is a hallmark of high-risk myeloma which is associated with inferior overall survival—data from the Ukmrc Myeloma XI trial. Blood 2018;132:122–122.

    Article  Google Scholar 

  24. Lonial S, Boise LH, Kaufman J. How I treat high-risk myeloma. Blood Am Soc Hematol. 2015;126:1536–43.

    CAS  Google Scholar 

  25. Gahrton G, Iacobelli S, Björkstrand B, Hegenbart U, Gruber A, Greinix H, et al. Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. Blood 2013;121:5055–63.

    Article  CAS  Google Scholar 

  26. López-Corral L, Caballero-Velázquez T, López-Godino O, Rosiñol L, Pérez-Vicente S, Fernandez-Avilés F, et al. Response to novel drugs before and after allogeneic stem cell transplantation in patients with relapsed multiple myeloma. Biol Blood Marrow Transpl. 2019;25:1703–12.

    Article  Google Scholar 

  27. Greil C, Engelhardt M, Ihorst G, Schoeller K, Bertz H, Marks R, et al. Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life. Haematologica 2019;104:370–9.

    Article  CAS  Google Scholar 

  28. Nair AP, Walker P, Kalff A, Bergin K, Hocking J, Avery S, et al. Adverse impact of high donor CD3+ cell dose on outcome following tandem auto-NMA allogeneic transplantation for high-risk myeloma. Bone Marrow Transpl. 2017;52:839–45.

    Article  CAS  Google Scholar 

  29. Donato ML, Siegel DS, Vesole DH, McKiernan P, Nyirenda T, Pecora AL, et al. The graft-versus-myeloma effect: chronic graft-versus-host disease but not acute graft-versus-host disease prolongs survival in patients with multiple myeloma receiving allogeneic transplantation. Biol Blood Marrow Transpl. 2014;20:1211–6.

    Article  CAS  Google Scholar 

  30. Kröger N, Zabelina T, Klyuchnikov E, Kropff M, Pflüger KH, Burchert A, et al. Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients. Bone Marrow Transpl. 2013;48:403–7.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Malignant Haematology and Stem Cell Transplantation Service, Department of Clinical Haematology, The Alfred Hospital, Melbourne, VIC, Australia

    Joanne L. C. Tan, Tongted Das, David Kliman, Jenny Muirhead, Anna Kalff, Patricia Walker & Andrew Spencer

  2. Department of Pathology, The Alfred Hospital, Melbourne, VIC, Australia

    Malgorzata Gorniak

  3. Australian Centre for Blood Diseases, Monash University, Melbourne, VIC, Australia

    Anna Kalff & Andrew Spencer

Authors
  1. Joanne L. C. Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tongted Das
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David Kliman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jenny Muirhead
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Malgorzata Gorniak
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Anna Kalff
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Patricia Walker
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Andrew Spencer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew Spencer.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tan, J.L.C., Das, T., Kliman, D. et al. Evaluation of EuroFlow minimal residual disease measurement and donor chimerism monitoring following tandem auto-allogeneic transplantation for multiple myeloma. Bone Marrow Transplant 56, 1116–1125 (2021). https://doi.org/10.1038/s41409-020-01148-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-020-01148-y

This article is cited by

Search

Advanced search

Quick links